30 closest matches · ranked by relevance
Indolent Systemic Mastocytosis
Primary: Percent Change in Quality of Life (QoL) Using Mastocytosis Quality of Life Questionnaire (MC-QoL) — 38.98; 33.02 percentage of change in quality of life — p=0.7740
Systemic Mastocytosis, Aggressive (ASM) · Leukemia, Mast Cell · Hematological Non-mast Cell Lineage Disease (AHNMD)
Primary: Subjects With Clinical Response [Partial Response (PR) + Complete Response (CR)] — 25 participants
Leukemia
Primary: Percentage of Participants With Overall Response Rate (ORR) — 59.6 Percentage of participants — p=<0.001
Systemic Mastocytosis
Primary: Number of Participants With Objective Response — 0 Participants
Advanced Systemic Mastocytosis · Aggressive Systemic Mastocytosis · Systemic Mastocytosis With an Associated Hematologic Neoplasm
Primary: Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on…
Aggressive Systemic Mastocytosis · Mast Cell Leukemia · Systemic Mastocytosis
Primary: Overall Response Rate (ORR) Per Consensus International Response Criteria (Rate of Complete or Partial Remissions or Clinical Improvement) — 0 participants
Asthma · Mastocytosis · Mast Cell Activation Syndrome
Primary: Mast Cell Activation Test Results for Validation Group — 6; 2; 0; 4 Participants
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005
Chronic Myelomonocytic Leukemia · Chronic Myeloid Leukemia · Polycythemia Vera
Primary: Number of Participants With a Complete Response (CR) — 0; 0; 2; 0 participants
Systemic Sclerosis
Primary: Improvement in the Modified Rodnan Skin Score — -6.6 units on a scale
Systemic Sclerosis, Scleroderma
Primary: Change From Baseline in Modified Rodnan Skin Score (MRSS) at Each Time Point of Analysis — 25.7; 6.58; 5.97; 8.34 units on a scale
Alveolitis · Systemic Sclerosis
Primary: Treatment-related Adverse Events — 5 participants
Polycythemia Vera · Thrombocythemia
Primary: Number of Participants With Best Overall Response — 0; 3; 6 Participants
Systemic Sclerosis
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 71 Adverse Events
Myelofibrosis · Post-polycythemia Vera Myelofibrosis (PPV-MF) · Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Sclerotic Graft Versus Host Disease · Imatinib Mesylate
Primary: Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months — 94; 35; 16; 21 Percent change from baseline
Asthma
Primary: Change in Mean Methacholine Responsiveness as Assessed by the Provocation Concentration Causing a 20% Fall in Forced Expiratory Volume in One Second (FEV1) (PC20) at…
Myelodysplastic Syndromes
Primary: Number of Participants With Confirmed Responses (Complete Remission, Partial Remission, or Hematologic Improvement) as Defined by the International Working Group…
Mucosal Melanoma · Acral/Lentiginous Melanoma · Chronically Sun Damaged Melanomas
Primary: Best Overall Response — 0; 0; 0; 7 participants
Lymphoma
Primary: Response to Treatment — 0; 9 participants
Anaphylaxis · Hypotension · Bronchospasm
Primary: Reduction in the Number and Timing of Anaphylactic Events in Subjects With a History of Frequent Idiopathic Anaphylaxis. — 32; 6 percentage of change of events
Urticaria Chronic
Primary: Time to 50% Decline in Clinical Symptoms Measured by the Urticaria Activity Score Seven Day(UAS7) — 23; 12 days
Graft Versus Host Disease · Systemic Scleroderma
Primary: Significant Clinical Response — 9; 10 participants
Lymphoma
Primary: Parts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE) — 10; 6 participants
Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)
Primary: Best Tumor Response (Core) — 0; 1; 49; 49 participants
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 7 participants
Symptomatic Dermographism
Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Sarcoma · Gastrointestinal Stromal Tumors
Primary: 2-year Relapse Free Survival Rate — 93.6 percentage of participants
Mycosis Fungoides · Sezary Syndrome
Primary: Efficacy of Nonmyeloablative Preparative Regimen — 4 Participants